Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

as a re- sult of PSA screening. But screening picks up many cancers that will never become fatal. This ‘overdiagnosis’ is thought to occur in ~40% of positive screens with signifi cant risks from treatment including urinary incontinence, erectile dysfunc- tion, and IHD. This balance of risk versus benefi t means that population screening for prostate cancer using PSA is not recommended. Despite this, any patient >50yrs (or >45yrs if high risk) can request PSA testing in primary care. Interpret any PSA result in conjunction with digital rectal examination and other risk factors. __OOHHCCMM__1100ee..iinnddbb 553300 0022//0055//22001177 1199::0088 erac evitaillap dna ygolocnO Table 11.4 Summary of tumour markers Tumour marker Relevant cancer Use Other associated cancers Associated benign conditions Alpha-fetoprotein Germ cell/testicular Diagnosis, monitoring treat- Colorectal; gastric; hepatobiliary; lung Cirrhosis; pregnancy; neural tube defects (FP) ment, detecting recurrence Hepatocellular Calcitonin Medullary thyroid Diagnosis, monitoring treat- None known C-cell hyperplasia ment, detecting recurrence Cancer antigen Ovarian Monitoring ovarian cancer. Breast; cervical; endometrial; hepatocellular; Liver disease; cystic fi brosis; pancreatitis; urinary reten- (CA)125 Prognosis after chemotherapy lung; non-Hodgkin’s lymphoma; pancreatic; tion; diabetes; heart failure; pregnancy; SLE; sarcoid; RA; medullary thyroid carcinoma; peritoneal; diverticulitis; IBS; endometriosis; fi broids uterine CA19–9 Pancreatic Monitoring pancreatic cancer
